Drug Companies Headed Toward Improving Hep C Therapy
September 8, 2011
Dramatic Changes in Hepatitis C Treatment Expected to Continue
Steve Worland 9/6/11
Earlier this year the FDA approved telaprevir (Incivek) from Vertex Pharmaceuticals and boceprevir (Victrelis) from Merck for the treatment of hepatitis C. Both agents are protease inhibitors and represent the first approvals of direct acting antivirals for hepatitis C. Direct acting antivirals are a broad class of agents that act to block the growth of viruses by directly disrupting essential viral functions. The benefit of these drugs for hepatitis C follows the dramatic success of this class over the last 15 years in HIV. Now the future advances of direct acting antiviral therapy for hepatitis C is expected to follow a central theme of their use in HIV: that combination of multiple antivirals in a single treatment regimen will provide greater benefit than use of any one antiviral drug alone.
Continue reading this entire article:
Hepatitis in Assisted Living Facilities
Vaccine Hopes Strengthen as Hep C Vulnerability Realized